Jump to content
 







Main menu
    


Navigation  


●Main page
 ●Contents
 ●Current events
 ●Random article
 ●About Wikipedia
 ●Contact us
 ●Donate
  



Contribute  


●Help
 ●Learn to edit
 ●Community portal
 ●Recent changes
 ●Upload file
  







Search  

































●Create account

●Log in
 









●Create account
 ● Log in
  



Pages for logged out editors learn more  


●Contributions
 ●Talk
  


















Contents

   



(Top)
  


1 Legality  




2 See also  




3 References  




4 Further reading  




5 External links  













ETH-LAD






●Deutsch
 ●Hrvatski
 ●Русский
 ●Српски / srpski
 ●Srpskohrvatski / српскохрватски
  
Edit links
  








●Article
 ●Talk
  
















●Read
 ●Edit
 ●View history
  







Tools
    


Actions  


●Read
 ●Edit
 ●View history
  



General  


●What links here
 ●Related changes
 ●Upload file
 ●Special pages
 ●Permanent link
 ●Page information
 ●Cite this page
 ●Get shortened URL
 ●Download QR code
 ●Wikidata item
  



Print/export  


●Download as PDF
 ●Printable version
  















Appearance
    

 





From Wikipedia, the free encyclopedia
  

ETH-LAD
Clinical data
Other namesETH-LAD, 6-ethyl-6-nor-Lysergic acid diethylamide
Routes of
administration		Oral
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • Illegal in France[1]
    • Pharmacokinetic data
    MetabolismHepatic
    ExcretionRenal
    Identifiers

    • (6aR,9R)-N,N-diethyl-7-ethyl-4,6,6a,7,8,9-
      hexahydroindolo-[4,3-fg]quinoline-9-carboxamide

    CAS Number
    PubChem CID
    ChemSpider
    UNII
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC21H27N3O
    Molar mass337.467 g·mol−1
    3D model (JSmol)

    • CCN(C([C@@H]1C=C2C3=CC=CC4=C3C(C[C@H]2N(CC)C1)=CN4)=O)CC

    • InChI=1S/C21H27N3O/c1-4-23(5-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22-18)11-19(17)24(6-3)13-15/h7-10,12,15,19,22H,4-6,11,13H2,1-3H3/t15-,19-/m1/s1 checkY

    • Key:MYNOUXJLOHVSMQ-DNVCBOLYSA-N checkY

     ☒NcheckY (what is this?)  (verify)

    ETH-LAD, 6-ethyl-6-nor-lysergic acid diethylamide is an analogue of LSD. Its human psychopharmacology was first described by Alexander Shulgin in the book TiHKAL. ETH-LAD is a psychedelic drug similar to LSD, and is slightly more potent than LSD itself,[2] with an active dose reported at between 20 and 150 micrograms. ETH-LAD has subtly different effects to LSD, described as less demanding. The true tryptamine counterpart of ETH-LAD is MET, a simplified version of this structure.

    Legality[edit]

    On June 10, 2014, the UK Advisory Council on the Misuse of Drugs (ACMD) recommended that ETH-LAD be specifically named in the UK Misuse of Drugs Act as a class A drug despite not identifying it as ever having been sold or any harm associated with its use.[3] The UK Home office accepted this advice and announced a ban of the substance to be enacted on 6 January 2015.[4]

    ETH-LAD is illegal in Switzerland as of December 2015.[5]

    See also[edit]

    References[edit]

    1. ^ "Arrêté du 20 mai 2021 modifiant l'arrêté du 22 février 1990 fixant la liste des substances classées comme stupéfiants". www.legifrance.gouv.fr (in French). 20 May 2021.
  • ^ Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5. doi:10.1021/jm00147a022. PMID 4032428.
  • ^ Advisory Council on the Misuse of Drugs (ACMD) (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014.
  • ^ "The Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2014".
  • ^ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien". Der Bundesrat.

    • Further reading[edit]

    • Hoffman AJ, Nichols DE (September 1985). "Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives". Journal of Medicinal Chemistry. 28 (9): 1252–5. doi:10.1021/jm00147a022. PMID 4032428.
  • Watts VJ, Lawler CP, Fox DR, Neve KA, Nichols DE, Mailman RB (April 1995). "LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors". Psychopharmacology. 118 (4): 401–9. doi:10.1007/BF02245940. PMID 7568626. S2CID 21484356.
  • Niwaguchi T, Nakahara Y, Ishii H (May 1976). "[Studies on lysergic acid diethylamide and related compounds. IV. Syntheses of various amide derivatives of norlysergic acid and related compounds]". Yakugaku Zasshi. 96 (5): 673–8. doi:10.1248/yakushi1947.96.5_673. PMID 987200.
  • Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE (1994). "Lysergamides Revisited" (PDF). NIDA Research Monograph 146: Hallucinogens: An Update. United States Department of Health and Human Services. p. 52. Archived from the original (PDF) on 2015-07-23.
  • Brandt SD, Kavanagh PV, Westphal F, Elliott SP, Wallach J, Stratford A, et al. (October 2017). "6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD)". Drug Testing and Analysis. 9 (10): 1641–1649. doi:10.1002/dta.2196. PMC 6230477. PMID 28342178.

    • External links[edit]


    Stub icon

    This hallucinogen-related article is a stub. You can help Wikipedia by expanding it.

  • t
  • e

    • Retrieved from "https://en.wikipedia.org/w/index.php?title=ETH-LAD&oldid=1211055111"
    Categories: 
    ●Designer drugs
     ●Entheogens
     ●Lysergamides
     ●Serotonin receptor agonists
     ●Hallucinogen stubs
     Hidden categories: 
    ●CS1 French-language sources (fr)
     ●Articles with short description
     ●Short description matches Wikidata
     ●Drugs with non-standard legal status
     ●Chemical pages without DrugBank identifier
     ●Articles without KEGG source
     ●Drugs missing an ATC code
     ●Drugboxes which contain changes to verified fields
     ●Drugboxes which contain changes to watched fields
     ●All stub articles
      


    ●This page was last edited on 29 February 2024, at 16:35 (UTC).
    ●Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Mobile view


    Wikimedia Foundation
    Powered by MediaWiki